Expert Interview
Discussing the Topline Data from TEPEZZA (teprotutumab) in phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Ticker(s): HZNPInstitution: Emory Healthcare
- Director, Oculoplastics, Orbital and Cosmetic Surgery & James and Shirley Kuse Professorship in Ophthalmology at Emory.
- Center manages hundreds of patients with TED & on the SAB of Horizon Pharma.
- Research focus has included essential blepharospasm and orbital tumors; author or co-author of more than 80 articles in medical journals.
How many patients with CAS-TED do you treat?
Added By: wilson_adminWhat is your impression of the phase 4 data?
Will you use Tepezza in CAS-TED patients?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
